JP2016538328A - Ｐｄｅ４阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 - Google Patents

Ｐｄｅ４阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 Download PDF

Info

Publication number
JP2016538328A
JP2016538328A JP2016545257A JP2016545257A JP2016538328A JP 2016538328 A JP2016538328 A JP 2016538328A JP 2016545257 A JP2016545257 A JP 2016545257A JP 2016545257 A JP2016545257 A JP 2016545257A JP 2016538328 A JP2016538328 A JP 2016538328A
Authority
JP
Japan
Prior art keywords
combination
nutritional supplement
forskolin
carnitine
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016545257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538328A5 (cg-RX-API-DMAC7.html
Inventor
シェール，ジャスティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016538328A publication Critical patent/JP2016538328A/ja
Publication of JP2016538328A5 publication Critical patent/JP2016538328A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2016545257A 2013-09-27 2014-09-27 Ｐｄｅ４阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 Pending JP2016538328A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361883433P 2013-09-27 2013-09-27
US61/883,433 2013-09-27
US201462046953P 2014-09-06 2014-09-06
US62/046,953 2014-09-06
US201462047055P 2014-09-07 2014-09-07
US62/047,055 2014-09-07
PCT/US2014/057923 WO2015048590A1 (en) 2013-09-27 2014-09-27 Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation

Publications (2)

Publication Number Publication Date
JP2016538328A true JP2016538328A (ja) 2016-12-08
JP2016538328A5 JP2016538328A5 (cg-RX-API-DMAC7.html) 2018-09-13

Family

ID=52740399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545257A Pending JP2016538328A (ja) 2013-09-27 2014-09-27 Ｐｄｅ４阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物

Country Status (7)

Country Link
US (4) US9149457B2 (cg-RX-API-DMAC7.html)
EP (1) EP3049101A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016538328A (cg-RX-API-DMAC7.html)
AU (2) AU2014324608B2 (cg-RX-API-DMAC7.html)
CA (1) CA2925318C (cg-RX-API-DMAC7.html)
IL (1) IL244743B (cg-RX-API-DMAC7.html)
WO (1) WO2015048590A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048590A1 (en) 2013-09-27 2015-04-02 Sher Justin Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation
CA3063174A1 (en) 2017-05-12 2018-11-15 Innovus Pharmaceuticals, Inc. Therapeutic methods and compositions
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US20190167699A1 (en) 2017-12-01 2019-06-06 Innovus Pharmaceuticals, Inc. Prostate function support formula
US10500199B2 (en) 2017-12-01 2019-12-10 Innovus Pharmaceuticals, Inc. Nutritional supplement for increasing cognitive functions
US10758505B2 (en) 2017-12-01 2020-09-01 Innovus Pharmaceuticals, Inc. Therapeutic compositions and methods
US10864205B2 (en) 2017-12-01 2020-12-15 Innovus Pharmaceuticals, Inc. Nutritional supplement for improving sexual health in men and women
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IT202000006094A1 (it) * 2020-03-23 2021-09-23 A M Italy S R L Composizione per l’uso nella terapia, in particolare per la cura dell’alzheimer
US11999694B2 (en) 2021-10-29 2024-06-04 Sensorium Therapeutics, Inc. Delivery of therapeutic alkaloid compounds
US12410128B1 (en) 2022-04-15 2025-09-09 Sensorium Therapeutics, Inc. Therapeutic alkaloid compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925377A (en) * 1997-08-07 1999-07-20 Nova Pharmaceutical Co. Dietary supplement composition
WO2000062812A1 (en) * 1999-04-20 2000-10-26 Advocare International Llc Nutritional composition for improved cognitive performance
US20060171938A1 (en) * 2005-02-03 2006-08-03 Stock Jeffry B Compositions and methods for enhancing cognitive function
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US20130034530A1 (en) * 2011-04-29 2013-02-07 David R. Fantz Dietary Supplement Cognitive Support System

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
NZ543486A (en) * 2005-11-10 2009-03-31 Fonterra Corporate Res And Dev Compositions of CIS-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof
US8501581B2 (en) 2006-03-29 2013-08-06 Micron Technology, Inc. Methods of forming semiconductor constructions
WO2007123699A1 (en) * 2006-03-30 2007-11-01 Dana-Farber Cancer Institute, Inc. Methods and compositions for modulating melanogenesis by using a mclr agonist
US20080044390A1 (en) * 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
WO2008153426A1 (en) * 2007-06-15 2008-12-18 Sealord Group Limited Anti-inflammatory composition and use thereof
US8029830B2 (en) * 2008-04-18 2011-10-04 Nuvocare Health Services Inc. Composition and method for promoting internal health and external appearance
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
US8552051B2 (en) 2009-03-20 2013-10-08 H. L. Hall & Sons Limited Use of pharmaceutical compositions containing mesembrenone
WO2011003045A1 (en) 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
FR2948566B1 (fr) * 2009-07-30 2012-08-10 Expanscience Lab Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant
US8202525B2 (en) * 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
WO2015048590A1 (en) 2013-09-27 2015-04-02 Sher Justin Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925377A (en) * 1997-08-07 1999-07-20 Nova Pharmaceutical Co. Dietary supplement composition
WO2000062812A1 (en) * 1999-04-20 2000-10-26 Advocare International Llc Nutritional composition for improved cognitive performance
US20060171938A1 (en) * 2005-02-03 2006-08-03 Stock Jeffry B Compositions and methods for enhancing cognitive function
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US20130034530A1 (en) * 2011-04-29 2013-02-07 David R. Fantz Dietary Supplement Cognitive Support System

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ＢＲＡＩＮ ＲＥＳＥＡＲＣＨ, vol. 405, no. 2, JPN6018016032, 1987, pages 371 - 374, ISSN: 0004075288 *
ＮＥＵＲＯＰＳＹＣＨＯＰＨＡＲＭＡＣＯＬＯＧＹ, vol. [online], JPN6018016033, 1 August 2013 (2013-08-01), pages 10 - 1038, ISSN: 0004075289 *
ビタミン, vol. Ｖｏｌ．８３，Ｎｏ．５−６, JPN6019026939, 2009, pages 305 - 306, ISSN: 0004075290 *
脂質栄養学, vol. 19, no. 1, JPN6018016031, 2010, pages 19 - 23, ISSN: 0004075287 *

Also Published As

Publication number Publication date
US20150093458A1 (en) 2015-04-02
US10058529B2 (en) 2018-08-28
US9149457B2 (en) 2015-10-06
CA2925318A1 (en) 2015-04-02
EP3049101A1 (en) 2016-08-03
AU2014324608B2 (en) 2019-08-08
US20160213642A1 (en) 2016-07-28
US20200147033A1 (en) 2020-05-14
EP3049101A4 (en) 2018-01-10
US20190274996A1 (en) 2019-09-12
IL244743B (en) 2020-11-30
AU2019219780A1 (en) 2019-09-12
AU2014324608A1 (en) 2016-04-28
IL244743A0 (en) 2016-04-21
CA2925318C (en) 2021-01-19
WO2015048590A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
JP2016538328A (ja) Ｐｄｅ４阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物
Dludla et al. Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-β-D-glucoside
Chawla et al. Radioprotective and antioxidant activity of fractionated extracts of berries of Hippophae rhamnoides
Ku et al. Garlic and its active metabolite allicin produce endothelium-and nitric oxide-dependent relaxation in rat pulmonary arteries.
JP2008110996A (ja) 体脂肪低減用組成物
Ajagun‐Ogunleye et al. Evaluation of the anti‐aging and antioxidant action of Ananas sativa and Moringa oleifera in a fruit fly model organism
Pathak et al. Standardized root extract of Withania somnifera and Withanolide A exert moderate vasorelaxant effect in the rat aortic rings by enhancing nitric oxide generation
Giacalone et al. Blueberry polyphenols and neuroprotection
Angelone et al. Distinct signalling mechanisms are involved in the dissimilar myocardial and coronary effects elicited by quercetin and myricetin, two red wine flavonols
Ahmad et al. Development of White Cabbage, Coffee, and Red Onion Extracts as Natural Phosphodiesterase‐4B (PDE4B) Inhibitors for Cognitive Dysfunction: in Vitro and In Silico Studies
Walker et al. The use of bergamot-derived polyphenol fraction in cardiometabolic risk prevention and its possible mechanisms of action
US20190209491A1 (en) Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache
US20150157672A1 (en) Kits and methods for sustained weight loss
da Rocha Lapa et al. Vasorelaxant and hypotensive effects of the extract and the isolated flavonoid rutin obtained from Polygala paniculata L.
US8840937B2 (en) Composition and method for recovery from mild traumatic brain injury
CA2810793C (en) Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
Luhata et al. Natural products from Odontonema strictum promote neurite outgrowth in neuronal PC12 cells
JP4145659B2 (ja) 細辛抽出物を含有する脳細胞保護及び記憶力増進用組成物
US20220313675A1 (en) Anti-Aging Telomere-Strengthening NAD+ Sirtuin Dietary Supplement Composition
Subhan et al. Pharmacological Attributes of Hesperidin
Wang et al. L-theanine as a promising agent on brain health-promoting foods–a review
Do et al. Study on the analgesic, anti-inflammatory and hypouricemic effects of 50% ethanolic extract from Jasminum subtriplinerve Blume
US20130189380A1 (en) Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
Allen et al. Terminalia glaucescens ethanol stem extract induces vasorelaxation via nitric oxide/guanylyl cyclase/cyclic guanosine monophosphate pathway in the aortic smooth muscle of male Wistar rats
KR20240073178A (ko) 부채마 추출물 또는 디오신을 포함하는 기억력 개선, 신경염증 억제, 신경세포 사멸 억제, 또는 자가포식작용 촉진용 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180615

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190426

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190531

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190607

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190712

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190719

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200327

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200403

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200619

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201016

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201113

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201113